About Lophora

Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders.

Lophora Founders Team at BioInnovation Institute (October 2020). From left: Emil Märcher-Rørsted, Jesper Langgaard Kristensen, Bo Tandrup, Anders Asbjørn Jensen.
Anders Asbjørn Jensen and Emil Märcher-Rørsted in the laboratories in Copenhagen (October 2020)

The company has identified and patented a new class of proprietary ligands. The lead compound LPH-5 is a highly selective small-molecule agonist of the Serotonin 5-HT2AR and exhibits robust CNS exposure, target engagement and efficacy in animal models of depression. LPH-5 has now entered Phase I trials.

After being spun out from University of Copenhagen Lophora has been funded by BII (Novo Nordisk Foundation), Venture Funds, family offices and experienced biotech investors.

Corporate directory

Lophora ApS
Gyldenlundsvej 21, 1
2920 Charlottenlund
Greater Copenhagen Area
Denmark

Phone: +45 51 86 84 82
Registered office: Charlottenlund
CVR no.: 39 87 10 33
Financial year: 01.01 – 31.12

Visiting Address
Herlev Hovedgade 195A
2730 Herlev

Auditor
Beierholm Accountants
CVR no. 32 89 54 68
Thomas Thomsen, State Authorized Public Accountant
MNE-no. mne34079

Lawyer
DLA Piper
CVR no. 35 20 93 52
Martin Lavesen, Country Managing Partner